



Kentucky Medicaid Drug Management Review Advisory Board (DMRAB) Meeting



Tina Hawkins, PharmD
Clinical Program Manager
November 4, 2010

Agenda




- Welcome
- Approval of the August 12, 2010 Meeting Minutes
- Old Business
 - Suboxone®/Subutex® Utilization
 - Atypical Antipsychotics
 - Branded Anticonvulsants
 - Top Prescribers
 - Top Recipients
- New Business
 - Population Statistics
 - Utilization Data
 - ProDUR
 - RetroDUR
 - Future DUR Activities
- Public Comment
- Adjournment

Old Business


- Suboxone[®]/Subutex[®] with Opioids
- Atypical Antipsychotics
 - Utilization with Drugs that Could Exacerbate Psychosis
 - Multiple Prescribers
- Branded Anticonvulsants
- Top Prescribers
- Top Recipients

Suboxone[®]/Subutex[®] Utilization




The PA requirements started on 2/1/2010

Suboxone[®]/Subutex[®] Utilization




The PA requirements started on 2/1/2010

Suboxone[®]/Subutex[®] Utilization




The PA requirements started on 2/1/2010

Suboxone®/Subutex® Utilization with Narcotic




- Patients Without Narcotic in 30 Days
- 2 Narcotics in 30 Days
- 1 Narcotic in 30 Days

Suboxone®/Subutex® Utilization with Benzodiazepine




Suboxone[®]/Subutex[®] Utilization with Opioids




- Patients Without Opioid in 30 Days
- 2 Opioids in 30 Days
- 1 Opioid in 30 Days


Antipsychotic Utilization with Drugs that May Exacerbate Psychosis



Recipients with Multiple Antipsychotic Prescribers




Utilization of Branded Anticonvulsants



- **Diagnosis other than Epilepsy**
- **Patients with Diagnosis of Epilepsy**

Utilization of Branded Anticonvulsants



Top Ten

Prescribers

All Narcotics

Prescriber	3Q2010				
	Claims	Total Cost	Unique Recipients	Avg Claims Per Recipient	Avg Cost Per Recipient
1	2,359	\$90,143	584	4.04	\$154.35
2	1,981	\$52,011	608	3.26	\$85.54
3	1,952	\$43,091	413	4.73	\$104.34
4	1,934	\$31,089	790	2.48	\$39.35
5	1,752	\$101,328	548	3.2	\$184.91
6	1,712	\$72,049	535	3.2	\$134.67
7	1,684	\$22,407	649	2.59	\$34.52
8	1,645	\$43,659	346	4.75	\$126.18
9	1,557	\$11,613	288	5.41	\$40.32
10	1,515	\$49,524	422	3.59	\$117.36

Benzodiazepines

Prescriber	3Q2010				
	Claims	Total Cost	Unique Recipients	Avg Claims Per Recipient	Avg Cost Per Recipient
1	1,353	\$13,413	558	2.42	\$24.04
2	1,016	\$8,658	437	2.32	\$19.81
3	808	\$3,849	155	5.21	\$24.83
4	712	\$5,268	250	2.84	\$21.07
5	654	\$4,594	261	2.51	\$17.60
6	638	\$5,789	247	2.58	\$23.44
7	612	\$3,595	88	6.95	\$40.85
8	598	\$3,206	168	3.56	\$19.08
9	571	\$4,432	113	5.05	\$39.22
10	549	\$3,951	184	2.98	\$21.47

Long-Acting Narcotic Analgesics



Prescriber	3Q2010				
	Claims	Total Cost	Unique Recipients	Avg Claims Per Recipient	Avg Cost Per Recipient
1	272	\$97,181	84	3.24	\$1,156.92
2	251	\$69,480	114	2.2	\$609.47
3	185	\$41,230	67	2.76	\$615.38
4	185	\$47,353	95	1.95	\$498.45
5	130	\$60,170	47	2.77	\$1,280.21
6	122	\$32,418	46	2.65	\$704.74
7	92	\$17,733	51	1.81	\$347.70
8	81	\$20,902	39	2.08	\$535.95
9	79	\$11,810	40	1.98	\$295.24
10	73	\$24,055	47	1.55	\$511.81

Short-Acting Narcotic Analgesics



Prescriber	3Q2010				
	Claims	Total Cost	Unique Recipients	Avg Claims Per Recipient	Avg Cost Per Recipient
1	1,291	\$25,073	395	3.27	\$63.48
2	1,229	\$20,409	428	2.87	\$47.69
3	1,164	\$22,939	383	3.04	\$59.89
4	970	\$20,457	386	2.51	\$53.00
5	852	\$29,351	391	2.18	\$75.07
6	812	\$11,340	277	2.93	\$40.94
7	806	\$34,087	336	2.34	\$101.45
8	777	\$11,233	240	3.24	\$46.81
9	740	\$32,376	297	2.49	\$109.01
10	732	\$29,340	330	2.22	\$88.91

Top Ten

Recipients

All Narcotics

Recipient	3Q2010		
	Drugs	Total Cost	Unique Prescribers
1	9	\$1,194.60	4
2	8	\$91.08	5
3	8	\$1,865.34	4
4	8	\$1,076.18	4
5	8	\$636.68	4
6	8	\$1,398.05	3
7	8	\$1,201.65	3
8	8	\$198.25	1
9	7	\$412.21	5
10	7	\$428.69	3

All Narcotics

Recipient	3Q2010					
	Drug Count	Total Cost	Unique Prescribers	Drugs	QTY	Diagnosis
1	9	\$1,194.60	4	Ryzolt™	60	N/A
				hydrocodone-APAP	1	
				tramadol	300	
				propoxyphene-APAP	60	
				promethazine-codeine	120	
				Lyrica®	180	
				Duragesic®	10	
				diazepam	1	
				clonazepam	90	

All Narcotics

Recipient	3Q2010					
	Drug Count	Total Cost	Unique Prescribers	Drugs	QTY	Diagnosis
2	8	\$91.08	5	zolpidem	7	N/A
				tramadol	140	
				oxycodone- ibuprofen	28	
				oxycodone- APAP	10	
				oxycodone	20	
				hydrocodone -APAP	30	
				clonazepam	90	
				alprazolam	45	

All Narcotics

Recipient	3Q2010					
	Drug Count	Total Cost	Unique Prescribers	Drugs	QTY	Diagnosis
3	8	\$1,865.34	4	fentanyl	10	Chronic Pain Kidney/Bladder CA Lung CA Lumbago
				zolpidem	30	
				oxycodone- APAP	80	
				morphine CR	20	
				OxyContin®	112	
				clonazepam	30	
				oxycodone	140	
				alprazolam	168	

All Narcotics

Recipient	3Q2010					
	Drug Count	Total Cost	Unique Prescribers	Drugs	QTY	Diagnosis
4	8	\$1,076.18	4	zolpidem	90	OA Chronic Pain Lumbago
				morphine IR	60	
				methadone	597	
				lorazepam	270	
				diphenoxylate-atropine	20	
				clonazepam	49	
				butorphanol	160	
				alprazolam	120	

All Narcotics

Recipient	3Q2010					
	Drug Count	Total Cost	Unique Prescribers	Drugs	QTY	Diagnosis
5	8	\$636.68	4	methadone	35	N/A
				hydrocodone -APAP	30	
				alprazolam	60	
				tramadol	75	
				oxycodone- APAP	45	
				Duragesic®	10	
				oxycodone	90	
				clonazepam	35	

All Narcotics

Recipient	3Q2010					
	Drug Count	Total Cost	Unique Prescribers	Drugs	QTY	Diagnosis
6	8	\$1,398.05	3	clonazepam	205	N/A
				Adderall XR®	60	
				Lyrica®	120	
				hydrocodone-APAP	300	
				butorphanol	5	
				amphetamine salts	60	
				pentazocine-naloxone	30	
				Kadian®	60	

All Narcotics



Recipient	3Q2010					
	Drug Count	Total Cost	Unique Prescribers	Drugs	QTY	Diagnosis
7	8	\$1,201.65	3	OxyContin®	180	Anxiety Pain in Joint, Shoulder/Leg
				oxycodone/- APAP	116	
				oxycodone	30	
				morphine ER	90	
				lorazepam	1	
				hydrocodone -APAP	1	
				diazepam	119	
				alprazolam	273	

All Narcotics

Recipient	3Q2010					
	Drug Count	Total Cost	Unique Prescribers	Drugs	QTY	Diagnosis
8	8	\$198.25	1	Tussionex®	180	N/A
				zolpidem	20	
				promethazin e-codeine	160	
				tramadol	150	
				diazepam	150	
				hydrocodone -APAP	20	
				alprazolam	120	
				oxycodone- APAP	10	

All Narcotics

Recipient	3Q2010					
	Drug Count	Total Cost	Unique Prescribers	Drugs	QTY	Diagnosis
9	7	\$412.21	5	Vyvanse™	60	N/A
				tramadol	480	
				propoxyphene- APAP	30	
				hydrocodone- APAP	36	
				oxycodone- APAP	18	
				clonazepam	360	
				alprazolam	48	

All Narcotics

Recipient	3Q2010					
	Drug Count	Total Cost	Unique Prescribers	Drugs	QTY	Diagnosis
10	7	\$428.69	3	temazepam	60	Acute Post-Op Pain Pain in Joint/Pelvic Region Back Pain Lumbago
				OxyContin®	48	
				oxycodone-APAP	420	
				morphine ER	20	
				hydrocodone-APAP	90	
				clonazepam	30	
				alprazolam	180	

Benzodiazepines

Recipient	3Q2010		
	Drugs	Total Cost	Unique Prescribers
1	3	\$43.11	3
2	3	\$16.13	3
3	3	\$65.66	2
4	3	\$31.68	2
5	3	\$18.85	2
6	3	\$81.64	1
7	3	\$31.35	1
8	3	\$27.41	1
9	3	\$18.78	1
10	2	\$258.19	1

Benzodiazepines

Recipient	3Q2010					
	Drug Count	Total Cost	Unique Prescribers	Drugs	QTY	Diagnosis
1	3	\$43.11	3	alprazolam	360	N/A
				diazepam	60	
				chlordiazepoxide	30	
2	3	\$16.13	3	diazepam	25	Opioid Dependence Alcoholism Continuous Sedative, Hypnotic or Anxiolytic Dependence
				chlordiazepoxide	32	
				alprazolam	20	

Benzodiazepines

Recipient	3Q2010					
	Drug Count	Total Cost	Unique Prescribers	Drugs	QTY	Diagnosis
3	3	\$65.66	2	alprazolam	30	N/A
				lorazepam	360	
				diazepam	60	
4	3	\$31.68	2	diazepam	90	N/A
				lorazepam	120	
				alprazolam	28	

Benzodiazepines

Recipient	3Q2010					
	Drug Count	Total Cost	Unique Prescribers	Drugs	QTY	Diagnosis
5	3	\$18.85	2	lorazepam	30	N/A
				chlordiazepoxide	60	
				diazepam	30	
6	3	\$81.64	1	lorazepam	1	Anxiety
				diazepam	119	
				alprazolam	339	

Benzodiazepines

Recipient	3Q2010					
	Drug Count	Total Cost	Unique Prescribers	Drugs	QTY	Diagnosis
7	3	\$31.35	1	alprazolam	120	N/A
				lorazepam	90	
				diazepam	90	
8	3	\$27.41	1	lorazepam	60	Personal History of Psychological Trauma
				diazepam	60	
				alprazolam	180	

Benzodiazepines

Recipient	3Q2010					
	Drug Count	Total Cost	Unique Prescribers	Drugs	QTY	Diagnosis
9	3	\$18.78	1	lorazepam	45	N/A
				diazepam	30	
				alprazolam	30	
10	2	\$258.19	1	alprazolam ER	181	N/A
				alprazolam	90	

Short-Acting Narcotic Analgesics

Recipient	3Q2010		
	Drugs	Total Cost	Unique Prescribers
1	5	\$197.65	6
2	5	\$213.99	2
3	4	\$596.60	7
4	4	\$88.23	7
5	4	\$102.18	4
6	4	\$283.61	2
7	3	\$131.32	7
8	3	\$243.36	6
9	3	\$78.15	5
10	3	\$117.76	3

Short-Acting Narcotics



Recipient	3Q2010					
	Drug Count	Total Cost	Unique Prescribers	Drugs	QTY	Diagnosis
1	5	\$197.65	6	tramadol	120	N/A
				propoxyphene-APAP	20	
				oxycodone	120	
				hydrocodone-APPA	255	
				oxycodone-APAP	50	

Short-Acting Narcotics



Recipient	3Q2010					
	Drug Count	Total Cost	Unique Prescribers	Drugs	QTY	Diagnosis
2	5	\$213.99	2	tramadol- APAP	100	Pain in Joint of Lower Leg Back Pain Peripheral Neuropathy
				oxycodone- APAP	50	
				hydrocodone- APAP	120	
				meperidine	40	
				methadone	360	

Short-Acting Narcotics



Recipient	3Q2010					
	Drug Count	Total Cost	Unique Prescribers	Drugs	QTY	Diagnosis
3	4	\$596.60	7	oxycodone- APAP	530	N/A
				tramadol	116	
				morphine solution	120	
				hydrocodone- APAP	116	

Short-Acting Narcotics



Recipient	3Q2010					
	Drug Count	Total Cost	Unique Prescribers	Drugs	QTY	Diagnosis
4	4	\$88.23	7	tramadol- APAP	12	Chronic Cholecystitis Gallbladder Disease
				oxycodone	20	
				oxycodone- APAP	60	
				hydrocodone- APAP	84	

Short-Acting Narcotics



Recipient	3Q2010					
	Drug Count	Total Cost	Unique Prescribers	Drugs	QTY	Diagnosis
5	4	\$102.18	4	propoxyphene- APAP	10	N/A
				hydrocodone- APAP	102	
				oxycodone- APAP	70	
				tramadol- APAP	24	

Short-Acting Narcotics



Recipient	3Q2010					
	Drug Count	Total Cost	Unique Prescribers	Drugs	QTY	Diagnosis
6	4	\$283.61	2	oxycodone- APAP	270	N/A
				hydrocodone- APAP	60	
				oxycodone	240	
				tramadol	75	

Short-Acting Narcotics



Recipient	3Q2010					
	Drug Count	Total Cost	Unique Prescribers	Drugs	QTY	Diagnosis
7	3	\$131.32	7	hydrocodone-APAP	31	N/A
				tramadol	40	
				oxycodone-APAP	122	

Short-Acting Narcotics



Recipient	3Q2010					
	Drug Count	Total Cost	Unique Prescribers	Drugs	QTY	Diagnosis
8	3	\$243.36	6	oxycodone- APAP	350	OA Arthropathy Joint Pain Lumbago Acute Pain
				methadone	71	
				hydrocodone- APAP	24	

Short-Acting Narcotics



Recipient	3Q2010					
	Drug Count	Total Cost	Unique Prescribers	Drugs	QTY	Diagnosis
9	3	\$78.15	5	oxycodone- APAP	105	Cellulitis
				hydrocodone- ibuprofen	6	
				hydrocodone- APAP	20	

Short-Acting Narcotics



Recipient	3Q2010					
	Drug Count	Total Cost	Unique Prescribers	Drugs	QTY	Diagnosis
10	3	\$117.76	3	tramadol-APAP	10	N/A
				oxycodone-APAP	135	
				hydrocodone-APAP	30	

Long-Acting Narcotic Analgesics

Recipient	3Q2010		
	Drugs	Total Cost	Unique Prescribers
1	3	\$1,494.51	3
2	3	\$1,754.46	2
3	3	\$1,757.82	1
4	3	\$1,719.33	1
5	3	\$1,417.29	1
6	2	\$2,037.01	2
7	2	\$9,790.40	1
8	2	\$3,641	1
9	2	\$3,323.10	1
10	2	\$1,400.57	1

Long-Acting Narcotics



Recipient	3Q2010					
	Drug Count	Total Cost	Unique Prescribers	Drugs	QTY	Diagnosis
1	3	\$1,494.51	3	OxyContin®	112	Chronic Pain Kidney/Bladder CA Lung CA Lumbago
				morphine ER	20	
				fentanyl	10	
2	3	\$1,754.46	2	OxyContin®	60	N/A
				Opana ER®	60	
				Duragesic®	20	

Long-Acting Narcotics



Recipient	3Q2010					
	Drug Count	Total Cost	Unique Prescribers	Drugs	QTY	Diagnosis
3	3	\$1,757.82	1	Ryzolt® ER	56	N/A
				Kadian ER®	114	
				Duragesic®	20	
4	3	\$1,719.33	1	OxyContin®	120	Liver CA
				morphine ER	246	
				Duragesic®	20	

Long-Acting Narcotics



Recipient	3Q2010					
	Drug Count	Total Cost	Unique Prescribers	Drugs	QTY	Diagnosis
5	3	\$1,417.29	1	OxyContin®	60	N/A
				Kadian® ER	60	
				Exalgo®	30	
6	2	\$2,037.01	2	OxyContin®	320	N/A
				fentanyl	106	

Long-Acting Narcotics



Recipient	3Q2010					
	Drug Count	Total Cost	Unique Prescribers	Drugs	QTY	Diagnosis
7	2	9,790.40	1	Duragesic®	120	N/A
				morphine sulfate ER	120	
8	2	\$3,641	1	Kadian® ER	224	N/A
				tramadol ER	140	

Long-Acting Narcotics



Recipient	3Q2010					
	Drug Count	Total Cost	Unique Prescribers	Drugs	QTY	Diagnosis
9	2	\$3,323.10	1	Kadian® ER	60	Pancreatic CA
				fentanyl	45	
10	2	\$1,400.57	1	Kadian® ER	90	N/A
				fentanyl	35	

Pharmacy Data

- Population Statistics
- Utilization Data
 - Total Population
 - Adult Population (age 19 and above)
 - Child Population (ages 0 through 18)
- Utilization by Disease States
 - Total Population
 - Adult Population (age 19 and above)
 - Child Population (ages 0 through 18)

Population

	3Q2010	3Q2009
Non-Dual Children (<19)	335,769	324,299
Non-Dual Adults (≥19) with Rx Limit	158,974	152,285
Dual Eligible Children	150	160
Dual Eligible Adults	88,500	84,464
Total Medicaid Population	583,393	561,208
Ave Pharmacy Utilizing Members per month < 19 (Children)	134,802	107,620
Ave Pharmacy Utilizing Members per month ≥19 (Adults)	108,312	134,559

Utilizing Members

	3Q2010	3Q2009
# Utilizing Members / Month	243,114	242,179
# Prescriptions / Month	915,197	915,544
Total Amount Paid / Month	\$48,888,928	\$47,252,451
Average # Rxs / Utilizing Member / Month	3.77	3.79
Average Amount Paid / Claim	\$53.44	\$51.65
Average Amount Paid / Utilizing Member	\$201.41	\$195.65
Average Amount Paid / Eligible Member	\$83.80	\$84.20

Average Prescription Payment

	Percent of Total Prescriptions		Average Rx Payment	
	3Q2010	3Q2009	3Q2010	3Q2009
Single Source Brand	19.9%	19.6%	\$177.35	\$163.85
Multi-Source Brand	5.3%	7.5%	\$101.20	\$100.46
Generic	74.8%	72.9%	\$17.06	\$16.48

Utilization Data

Total Population

Top 10 Therapeutic Classes By Claim Volume

3Q2010			3Q2009	
Rank 2010	Therapeutic Class	# Claims 2010	Rank 2009	# Claims 2009
1	Narcotic Analgesics	162,918	1	156,440
2	Anticonvulsants	150,731	2	143,683
3	2 nd Generation Antihistamines	108,491	3	98,274
4	Anti-Anxiety Drugs	95,195	4	92,842
5	PPIs	88,810	5	88,109
6	NSAIDs-COX Inhibitor Type	84,776	6	82,635
7	Penicillins	74,367	7	75,030
8	ADHD Drugs	72,926	11	67,111
9	SSRIs	72,728	9	71,122
10	1 st Generation Antihistamines	71,325	8	73,039

Top 10 Therapeutic Classes By Payment Amount

3Q2010			3Q2009	
Rank 2010	Therapeutic Class	Payment Amount 2010	Rank 2009	Payment Amount 2009
1	Atypical Antipsychotics	\$17,394,759	1	\$16,734,217
2	ADHD Drugs	\$10,286,398	2	\$9,290,067
3	Narcotic Analgesics	\$7,909,233	5	\$6,976,180
4	PPIs	\$7,818,898	4	\$7,021,272
5	Anticonvulsants	\$7,644,812	3	\$7,619,308
6	Leukotriene Receptor Antagonists	\$4,627,258	6	\$3,988,174
7	Insulins	\$4,459,261	7	\$3,942,249
8	Beta-Adrenergic/ICS Combos	\$3,939,048	8	\$3,674,751
9	Statins	\$3,300,062	9	\$3,032,079
10	Beta-Adrenergic Agents	\$2,935,571	10	\$2,991,574

Top 10 Drugs By Claim Volume

3Q2010			3Q2009	
Rank 2010	Therapeutic Class	# Claims 2010	Rank 2009	# Claims 2009
1	hydrocodone/APAP	84,611	1	80,307
2	loratadine	61,976	2	62,000
3	amoxicillin	52,348	4	51,467
4	Prilosec [®] OTC	51,912	3	56,195
5	clonazepam	47,832	6	47,474
6	azithromycin	44,172	5	50,310
7	ibuprofen	44,124	7	43,214
8	lisinopril	37,233	8	34,224
9	Singulair [®]	37,060	9	33,877
10	gabapentin	35,368	13	28,711

Top 10 Drugs By Payment Amount

3Q2010			3Q2009	
Rank 2010	Therapeutic Class	Payment Amount 2010	Rank 2009	Payment Amount 2009
1	Abilify®	\$5,438,343	1	\$5,115,974
2	Singulair®	\$4,592,400	3	\$3,944,202
3	Nexium®	\$4,388,696	4	\$3,162,232
4	Seroquel®	\$4,123,391	2	\$4,277,334
5	Crestor®	\$2,826,367	7	\$2,538,814
6	Suboxone®	\$2,791,757	8	\$2,458,416
7	Advair Diskus®	\$2,615,741	5	\$2,694,388
8	Concerta®	\$2,399,703	10	\$2,156,323
9	Zyprexa®	\$2,330,430	9	\$2,243,660
10	Adderall XR®	\$2,282,385	6	\$2,574,754

Utilization Data

Adult Population (Ages \geq 19)

Top 10 Therapeutic Classes By Claim Volume

3Q2010			3Q2009	
Rank 2010	Therapeutic Class	# Claims 2010	Rank 2009	# Claims 2009
1	Narcotic Analgesics	152,280	1	145,463
2	Anticonvulsants	130,734	2	124,178
3	Anti-Anxiety Drugs	93,261	3	91,170
4	PPIs	78,801	4	78,867
5	SSRIs	60,898	5	59,874
6	NSAIDs	58,925	6	56,511
7	2 nd Gen Antihistamines	53,262	9	50,278
8	Analgesic/Antipyretics, Salicylates	52,954	7	54,730
9	Statins	52,253	10	46,505
10	Laxatives and Cathartics	46,866	8	51,238

Top 10 Therapeutic Classes By Payment Amount

3Q2010			3Q2009	
Rank 2010	Therapeutic Class	Payment Amount 2010	Rank 2009	Payment Amount 2009
1	Atypical Antipsychotics	\$12,346,744	1	\$11,425,508
2	Narcotic Analgesics	\$7,766,833	2	\$6,829,447
3	PPIs	\$6,765,399	3	\$6,066,327
4	Anticonvulsants	\$5,710,890	4	\$5,769,065
5	Insulins	\$3,823,042	5	\$3,360,382
6	Statins	\$3,288,125	6	\$3,019,282
7	Beta Adrenergic/ICS Combos	\$3,119,128	7	\$2,846,037
8	Lipotropics	\$2,302,326	9	\$1,883,137
9	Platelet Inhibitors	\$2,264,875	8	\$2,002,438
10	SNRIs	\$1,694,193	14	\$1,461,416

Top 10 Drugs By Claim Volume

3Q2010			3Q2009	
Rank 2010	Therapeutic Class	# Claims 2010	Rank 2009	# Claims 2009
1	hydrocodone/APAP	77,115	1	72,777
2	Prilosec OTC [®]	47,738	2	52,136
3	clonazepam	46,411	3	46,022
4	loratadine	37,498	4	37,596
5	lisinopril	36,221	5	33,356
6	gabapentin	34,841	8	28,228
7	alprazolam	34,062	7	30,392
8	aspirin EC	32,596	6	32,983
9	diazepam	27,511	9	27,414
10	levothyroxine	24,429	11	23,170

Top 10 Drugs By Payment Amount

3Q2010			3Q2009	
Rank 2010	Therapeutic Class	Payment Amount 2010	Rank 2009	Payment Amount 2009
1	Nexium®	\$4,077,988	2	\$2,945,019
2	Seroquel®	\$3,285,965	1	\$3,310,413
3	Abilify®	\$2,839,079	3	\$2,565,577
4	Crestor®	\$2,816,652	4	\$2,528,496
5	Suboxone®	\$2,766,956	5	\$2,430,501
6	Advair® Diskus	\$2,159,884	6	\$2,173,991
7	Plavix®	\$2,130,073	8	\$1,916,603
8	Zyprexa®	\$2,118,017	7	\$2,040,549
9	Lyrica®	\$1,683,364	9	\$1,703,297
10	Singulair®	\$1,450,897	14	\$1,302,049

Utilization Data

Child Population (Ages 0 through 18)

Top 10 Therapeutic Classes By Claim Volume

3Q2010			3Q2009	
Rank 2010	Therapeutic Class	# Claims 2010	Rank 2009	# Claims 2009
1	ADHD Drugs	64,111	1	62,459
2	Penicillins	55,385	2	55,380
3	2 nd Generation Antihistamines	55,205	3	47,820
4	Macrolides	31,985	4	36,962
5	Beta Adrenergic Agents	31,947	5	33,991
6	Glucocorticoids	30,643	6	31,391
7	NSAIDs	25,868	9	26,014
8	1st Generation Antihistamines	25,441	8	26,954
9	Leukotriene Receptor Antagonists	25,369	10	22,672
10	Non-Narc Antitus-1 st Gen Antihis-Decongest	23,237	7	28,889

Top 10 Therapeutic Classes By Payment Amount

3Q2010			3Q2009	
Rank 2010	Therapeutic Class	Payment Amount 2010	Rank 2009	Payment Amount 2009
1	ADHD Drugs	\$9,110,465	1	\$8,655,784
2	Atypical Antipsychotics	\$5,048,986	2	\$5,290,835
3	Leukotriene Receptor Antagonists	\$3,142,479	3	\$2,636,301
4	Glucocorticoids	\$1,997,243	4	\$2,109,848
5	Anticonvulsants	\$1,931,196	5	\$1,841,388
6	Beta Adrenergic Agents	\$1,407,746	6	\$1,443,358
7	Intranasal Steroids	\$1,358,976	7	\$1,153,819
8	Antihemophilic Factors	\$1,234,151	9	\$1,027,464
9	Growth Hormones	\$1,211,081	8	\$1,148,150
10	PPIs	\$1,052,535	12	\$948,860

Top 10 Drugs By Claim Volume

3Q2010			3Q2009	
Rank 2010	Therapeutic Class	# Claims 2010	Rank 2009	# Claims 2009
1	amoxicillin	41,472	1	40,475
2	azithromycin	30,539	2	35,059
3	Singulair®	25,358	4	22,654
4	loratadine	24,478	3	24,307
5	cetirizine	22,309	6	16,238
6	ibuprofen	20,506	5	20,503
7	Concerta®	14,730	7	14,523
8	sulfamethoxazole/trimethoprim	14,654	9	13,244
9	clonidine	14,520	8	13,801
10	Vyvanse®	14,058	11	11,945

Top 10 Drugs By Payment Amount

3Q2010			3Q2009	
Rank 2010	Therapeutic Class	Payment Amount 2010	Rank 2009	Payment Amount 2009
1	Singulair®	\$3,141,503	1	\$2,634,420
2	Abilify®	\$2,599,264	2	\$2,546,517
3	Concerta®	\$2,339,871	4	\$2,105,500
4	Adderall® XR	\$2,084,747	3	\$2,439,010
5	Vyvanse®	\$1,966,550	5	\$1,520,554
6	Nasonex®	\$1,024,900	7	\$1,067,216
7	Strattera®	\$1,021,760	6	\$1,080,886
8	Focalin XR®	\$919,386	10	\$765,464
9	azithromycin	\$852,463	8	\$963,768
10	Seroquel®	\$837,426	9	\$958,754

Utilization by Disease States

Total
Population

Disease States By Claim Volume

	3Q2010		3Q2009	
	Distinct Recipients	Claim Volume	Distinct Recipients	Claim Volume
Behavioral Health	8,807	31,789	7,814	26,811
Asthma/COPD	1,862	6,214	2,511	7,649
Chronic Pain	1,849	7,520	1,957	7,316
HTN	1,433	5,938	1,572	6,732
Diabetes	1,363	5,268	1,205	4,486
Cancer	588	1,226	518	1,065
HIV	22	132	32	169

Disease States By Payment Amount

Disease	Payment Amount 3Q2010	Payment Amount 3Q2009
Behavioral Health	\$20,549,840	\$26,730,312
Cancer	\$9,885,729	\$28,495,432
Diabetes	\$1,936,497	\$2,108,350
Asthma/COPD	\$843,913	\$1,329,567
Chronic Pain	\$791,804	\$1,017,786
HIV	\$257,023	\$728,175
HTN	\$155,498	\$317,170

Utilization Data

Adult Population (Ages \geq 19)

Disease States By Claim Volume

	3Q2010		3Q2009	
	Distinct Recipients	Claim Volume	Distinct Recipients	Claim Volume
Behavioral Health	6,764	24,698	6,060	20,950
Chronic Pain	1,823	7,440	1,908	7,194
HTN	1,418	5,889	1,531	6,588
Diabetes	1,282	4,988	1,141	4,267
Cancer	504	1,091	461	961
Asthma/COPD	225	877	300	1,021
HIV	22	132	31	167

Disease States By Payment Amount

Disease	Payment Amount 3Q2010	Payment Amount 3Q2009
Behavioral Health	\$14,381,285	\$18,823,576
Cancer	\$9,832,055	\$27,238,449
Diabetes	\$1,593,470	\$1,825,239
Chronic Pain	\$783,884	\$982,241
HIV	\$257,023	\$725,346
HTN	\$152,813	\$307,257
Asthma/COPD	\$98,784	\$87,202

Utilization Data

Child Population (Ages 0 through 18)

Disease States By Claim Volume

	3Q2010		3Q2009	
	Distinct Recipients	Claim Volume	Distinct Recipients	Claim Volume
Behavioral Health	2,050	7,091	1,761	5,861
Asthma/COPD	1,638	5,337	2,213	6,628
Cancer	84	135	57	104
Diabetes	81	280	64	219
Chronic Pain	27	80	49	122
HTN	15	49	41	144
HIV	0	0	1	2

Disease States By Payment Amount

Disease	Payment Amount 3Q2010	Payment Amount 3Q2009
Behavioral Health	\$6,168,556	\$7,906,736
Asthma/COPD	\$745,129	\$1,242,364
Diabetes	\$343,027	\$283,112
Cancer	\$53,674	\$1,256,982
Chronic Pain	\$7,920	\$35,546
HTN	\$2,685	\$9,913
HIV	\$0	\$2,830

Prospective Drug Utilization Review (ProDUR)

Edit Definitions

- **ProDUR Edit** – A computer system review of the member’s medication profile to identify potential drug therapy problems prior to dispensing the medication. Examples would include but not limited to:
 - Therapeutic Duplication (TD), Early Refill (ER), Max Dose, Drug to Gender, Drug to Drug, Drug to Inferred Disease, Geriatric and Pediatric Warnings
 - **Hard Edit** – These edits will cause the claim to deny at the point of sale (POS)
 - **Soft Edit** – These edits will cause an alert or warning message to be returned to the dispensing pharmacist to inform them of a potential problem. The pharmacist can bypass this message to process the claim after further evaluation and/or consultation with the patient or prescriber.

Edits Currently in POS System

ProDUR Conflict Type	Deny or Message Only	Provider Level Override or PA Required
Drug-to-Drug Interaction (DD)	Deny SL1	PA
Early Refill (ER) 90% tolerance	Deny	PA
Therapeutic Duplication (TD)	Deny	Provider PA-Stimulants
Duplicate Ingredient (ID)	Deny	Provider
Min/Max Daily Dose (LD, HD)	Message	N/A

ProDUR Summary

	3Q2010	3Q2009
HD, LD	555,064	485,269
DD	971,896	910,175
TD	1,145,707	1,206,175
ID	490,815	418,317
ER	295,340	227,341
Total Claims with ProDUR Alerts	1,891,634	1,758,764
Total Claims	2,804,740	2,736,863
% of Claims with ProDUR Alerts	67.4%	64.3%
% of Claims with ProDUR Alerts NOT filled.	19.8%	15.5%

Review of Retrospective Drug Utilization Review (RetroDUR) Activities

RetroDUR Activities

April 2010 Claims

- Polypharmacy (10 unique drugs, 1 pharmacy, 1 prescriber)
 - 165 Recipients identified for intervention
 - 452 Prescribers lettered
- Responses returned:
 - 14.2% response rate
 - Responses with approval ratings:
 - Very Useful = 4.7%
 - Useful = 36%
 - Somewhat Useful = 1.6%
 - Neutral = 9.4%
 - Not Useful = 20.3%

RetroDUR Activities



May 2010 Claims

- Benzodiazepines in patients 19 years of age and above without a diagnosis of anxiety, stress disorder, insomnia, or seizures
 - 160 Recipients chosen for intervention
 - 161 Prescribers lettered
- Responses returned:
 - 39.75% response rate
 - Responses with approval ratings:
 - Very Useful = 20.3%
 - Useful = 14
 - Somewhat Useful = 4.7%
 - Neutral = 15.6%
 - Not Useful = 14%

RetroDUR Activities

June 2010 Claims

- Benzodiazepines in patients 19 years of age and above without a diagnosis of anxiety, stress disorder, insomnia, or seizures; 475
- Short-acting narcotics duplicating for more than 6 weeks with a diagnosis of acute pain or headache; 342 exceptions
 - 149 Recipients chosen for intervention
 - 169 Prescribers lettered
- Responses returned:
 - 37.3% response rate
 - Responses with approval ratings:
 - Very Useful = 15.9%
 - Useful = 23.8%
 - Somewhat Useful = 4.8%
 - Neutral = 9.5%
 - Not Useful = 20.6%

Ideas for Future DUR Activities

- Polypharmacy; 7,604 exceptions; October activity
- Use of Antibiotics for URI – over-utilization and resistance; 14,975 exceptions
- FDA pregnancy category D drugs: 2,134 exceptions
- Benzo duplication; 1,852 exceptions
- Beers Criteria – Diazepam use in older adults; 1,406 exceptions
- Ibuprofen dose $\geq 3,200$ mg per day; 1,244 exceptions

Public Comment

Speaker	Representing	Topic/Drug
Anthony Tommasello, RPh, PhD, Field Medical Advisor	Reckitt Benckiser	Suboxone® Sublingual Film



Kentucky Medicaid Drug Management Review Advisory Board (DMRAB) Meeting

Next Meetings:

February 10, 2010

May 12, 2011

Tina Hawkins, PharmD
Clinical Program Manager
August 12, 2010